Patents Assigned to Epimmune, Inc.
-
Patent number: 9789181Abstract: The present invention provides novel artificial oligopeptides capable of binding HLA Class II molecules encoded by several alleles. The oligopeptides include the sequence AX1FVAAX2TLX3AX4A (SEQ ID NO:1), wherein X1 is H; X2 is selected from the group consisting of F, N, Y and W; X3 is H and X4 is selected from the group consisting of A, D and E. The invention also relates to large peptides comprising the oligopeptides, polynucleotides encoding the oligopeptides and larger peptides, as well as to compositions comprising the oligopeptides, peptides or polynucleotides. Also disclosed are methods for inducing immune responses.Type: GrantFiled: December 22, 2015Date of Patent: October 17, 2017Assignee: EPIMMUNE INC.Inventors: Florence Dal Degan, Mark J. Newman, Jeffery L. Alexander, Scott Southwood
-
Patent number: 9511134Abstract: The present invention provides polynucleotides and polypeptides capable of enhancing the immune response of a human in need of protection against influenza virus infection by administering in vivo, into a tissue of the human, at least one polynucleotide comprising one or more regions of nucleic acid encoding an influenza protein or a fragment, variant, or derivative thereof, or at least one polypeptide encoded therefrom. The present invention also relates to identifying and preparing influenza virus epitopes and to polynucleotides and polypeptides comprising such influenza virus epitopes. The present invention also relates to compositions and methods of use in the prevention and treatment of influenza virus infection.Type: GrantFiled: May 18, 2007Date of Patent: December 6, 2016Assignee: Epimmune Inc.Inventors: Jeffery L. Alexander, Pamuk A. Bilsel, Mark J. Newman
-
Publication number: 20160193316Abstract: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare Plasmodium falciparum epitopes, and to develop epitope-based vaccines directed towards malaria. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of malaria. In particular, this application discloses isolated peptides comprising oligopeptides, for example the oligopeptides LLACAGLAY, FLIFFDLFLV, FMKAVCVEV, VLAGLLGNV, GLIMVLSFL, KILSVFFLA, GLLGNVSTV, VLLGGVGLVL, ILSVSSFLFV, QTNFKSLLR, LACAGLAYK, ALFFIIFNK, LLACAGLAYK, HVLSHNSYEK, FILVNLLIFH, FQDEENIGIY, PSDGKCNLY, YYIPHQSSL, FYFILVNLL, KYLVIVFLI and KYKLATSVL, or isolated peptides conjugated with T helper peptides that are used as antigens in epitope-based vaccines to prevent and/or treat malaria.Type: ApplicationFiled: December 28, 2015Publication date: July 7, 2016Applicant: Epimmune Inc.Inventors: Alessandro Sette, John Sidney, Scott Southwood, Brian D. Livingston, Robert Chestnut, Denise Marie Baker, Esteban Celis, Ralph T. Kubo, Howard M. Grey
-
Patent number: 9340577Abstract: The present invention provides the means and methods for selecting immunogenic peptides and the immunogenic peptide compositions capable of specifically binding glycoproteins encoded by HLA alleles and inducing T cell activation in T cells restricted by the allele. One such peptide, NMLSTVLGV (SEQ ID NO: 183) is useful to elicit an immune response against influenza. The present invention also provides a heteropolymer of an isolated immunogenic peptide less than 15 amino acids in length comprising the oligopeptide NMLSTVLGV (SEQ ID NO: 183) and at least one different peptide.Type: GrantFiled: April 6, 2004Date of Patent: May 17, 2016Assignee: Epimmune Inc.Inventors: Howard M. Grey, Alessandro Sette, John Sidney, Scott Southwood, Ralph T. Kubo, Esteban Celis, Robert Chesnut, W. Martin Kast
-
Publication number: 20160114035Abstract: The present invention provides novel artificial oligopeptides capable of binding HLA Class II molecules encoded by several alleles. The oligopeptides include the sequence AX1FVAAX2TLX3AX4A (SEQ ID NO:1), wherein X1 is selected from the group consisting of W, F, Y, H, D, E, N, Q, I and K; X2 is selected from the group consisting of F, N, Y and W; X3 is selected from the group consisting of H and K, and X4 is selected from the group consisting of A, D and E, with the proviso that the oligopeptide sequence is not AKFVAAWTLKAAA. The invention also relates to larger peptides comprising the oligopeptides, polynucleotides encoding the oligopeptides and larger peptides, as well as to compositions comprising the oligopeptides, peptides or polynucleotides. Also disclosed are methods for inducing immune responses.Type: ApplicationFiled: December 22, 2015Publication date: April 28, 2016Applicant: Epimmune Inc.Inventors: Florence Dal Degan, Mark J. Newman, Jeffrey L. Alexander, Scott Southwood
-
Patent number: 9266930Abstract: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare Plasmodium falciparum epitopes, and to develop epitope-based vaccines directed towards malaria. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of malaria. In particular, this application discloses isolated peptides comprising oligopeptides, for example the oligopeptide GVSENIFLK, or isolated peptides conjugated with T helper peptides that are used as antigens in epitope-based vaccines to prevent and/or treat malaria.Type: GrantFiled: September 3, 1999Date of Patent: February 23, 2016Assignee: Epimmune Inc.Inventors: Alessandro Sette, John Sidney, Scott Southwood, Brian D. Livingston, Robert Chestnut, Denise Marie Baker, Esteban Celis, Ralph T. Kubo, Howard M. Grey
-
Patent number: 9249187Abstract: The present invention provides novel artificial oligopeptides capable of binding HLA Class II molecules encoded by several alleles. The oligopeptides include the sequence AX1FVAAX2TLX3AX4A (SEQ ID NO:1), wherein X1 is selected from the group consisting of W, F, Y, H, D, E, N, Q, I and K; X2 is selected from the group consisting of F, N, Y and W; X3 is selected from the group consisting of H and K, and X4 is selected from the group consisting of A, D and E, with the proviso that the oligopeptide sequence is not AKFVAAWTLKAAA. The invention also relates to larger peptides comprising the oligopeptides, polynucleotides encoding the oligopeptides and larger peptides, as well as to compositions comprising the oligopeptides, peptides or polynucleotides. Also disclosed are methods for inducing immune responses.Type: GrantFiled: January 26, 2010Date of Patent: February 2, 2016Assignee: Epimmune Inc.Inventors: Florence Dal Degan, Mark J. Newman, Jeffery L. Alexander, Scott Southwood
-
Publication number: 20120015401Abstract: The subject invention provides novel Plasmodium falciparum antigens and novel polynucleotides encoding these antigens. Also provided by the subject invention are methods of using these antigens and polynucleotides.Type: ApplicationFiled: July 25, 2011Publication date: January 19, 2012Applicants: U.S.A as Represented by the Secretary of the Navy, Office of Naval Research (Code 00CC), Epimmune Inc.Inventors: Alessandro Sette, Denise L. Doolan, Daniel J. Carucci, John Sidney, Scott Southwood
-
Publication number: 20110293646Abstract: The present invention provides novel artificial oligopeptides capable of binding HLA Class II molecules encoded by several alleles. The oligopeptides include the sequence AX1FVAAX2TLX3AX4A (SEQ ID NO:1), wherein X1 is selected from the group consisting of W, F, Y, H, D, E, N, Q, I and K; X2 is selected from the group consisting of F, N, Y and W; X3 is selected from the group consisting of H and K, and X4 is selected from the group consisting of A, D and E, with the proviso that the oligopeptide sequence is not AKFVAAWTLKAAA. The invention also relates to larger peptides comprising the oligopeptides, polynucleotides encoding the oligopeptides and larger peptides, as well as to compositions comprising the oligopeptides, peptides or polynucleotides. Also disclosed are methods for inducing immune responses.Type: ApplicationFiled: January 26, 2010Publication date: December 1, 2011Applicant: Epimmune Inc.Inventors: Florence Dal Degan, Mark J. Newman, Jeffery L. Alexander, Scott Southwood
-
Patent number: 8017745Abstract: The subject invention provides novel Plasmodium falciparum antigens and novel polynucleotides encoding these antigens. Also provided by the subject invention are methods of using these antigens and polynucleotides.Type: GrantFiled: December 8, 2003Date of Patent: September 13, 2011Assignees: Epimmune Inc., The United States of America as represented by the Secretary of the NavyInventors: Alessandro Sette, Denise L. Doolan, Daniel J. Carucci, John Sidney, Scott Southwood
-
Patent number: 7888472Abstract: The invention relates to the field of biology. In particular, it relates to multi-epitope nucleic acid and peptide vaccines and methods of designing such vaccines to provide increased immunogenicity.Type: GrantFiled: March 20, 2009Date of Patent: February 15, 2011Assignees: Epimmune Inc., GENimmune N.V.Inventors: Alessandro Sette, Robert Chesnut, Mark J. Newman, Brian D. Livingston, Lilia Maria Babe, Yiyou Chen, Lawrence M. Deyoung, Manley T. F. Huang, Scott D. Power
-
Publication number: 20060165719Abstract: the subject invention provides novel Plasmodium falciparum antigens and novel polynucleotides encoding these antigens. Also provided by the subject invention are methods of using these antigens and polynucleotides.Type: ApplicationFiled: December 8, 2003Publication date: July 27, 2006Applicant: Epimmune Inc.Inventors: Alessandro Sette, Denise Doolan, Daniel Carucci, John Sidney, Scott Southwood
-
Publication number: 20060093617Abstract: The present invention is directed to peptides, and nucleic acids encoding them, derived from the Hepatitis C Virus (HCV). The peptides are those which elicit a CTL and/or HTL response in a host. The invention is also directed to compositions and vaccines for prevention and treatment of HCV infection and diagnostic methods for detection of HCV exposure in patients.Type: ApplicationFiled: May 31, 2005Publication date: May 4, 2006Applicants: Innogenetics, N.V., EPIMMUNE INC.Inventors: Marie-Ange Buyse, Geert Maertens, Erik Depla, Ignace Lasters, Johan Desmet, Denise Baker, Robert Chesnut, Mark Newman, Alessandro Sette, John Sidney, Scott Southwood
-
Patent number: 7026443Abstract: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare human papillomavirus (HPV) epitopes, and to develop epitope-based vaccines directed towards HPV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HPV infection.Type: GrantFiled: August 15, 2000Date of Patent: April 11, 2006Assignee: Epimmune Inc.Inventors: Alessandro Sette, John Sidney, Scott Southwood, Robert Chesnut, Esteban Celis, Howard M. Grey
-
Publication number: 20050049197Abstract: This invention provides HLA-DR binding peptides, called “pan DR binding peptides” that are recognized by a broad spectrum of DR molecules. In particular, the present invention provides compositions comprising nucleic acid segments that encode such pan DR binding peptides, which are useful for enhancing the immune response to a desired immunogen.Type: ApplicationFiled: October 7, 2004Publication date: March 3, 2005Applicant: Epimmune Inc.Inventors: Alessandro Sette, Federico Gaeta, Howard Grey, John Sidney, Jeffery Alexander
-
Publication number: 20040157780Abstract: The present invention provides the means and methods for selecting immunogenic peptides and the immunogenic peptide compositions capable of specifically binding glycoproteins encoded by HLA-A2.1 allele and inducing T cell activation in T cells restricted by the A2.1 allele. The peptides are useful to elicit an immune response against a desired antigen.Type: ApplicationFiled: February 4, 2004Publication date: August 12, 2004Applicant: Epimmune Inc.Inventors: Howard M. Grey, Alessandro Sette, John Sidney
-
Patent number: 6689363Abstract: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to develop epitope-based vaccines directed towards HBV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HBV infection.Type: GrantFiled: January 27, 1999Date of Patent: February 10, 2004Assignee: Epimmune Inc.Inventors: Alessandro Sette, John Sidney, Scott Southwood, Maria A. Vitiello, Brian D. Livingston, Esteban Celis, Ralph T. Kubo, Howard M. Grey, Robert W. Chesnut
-
Patent number: 6602510Abstract: A composition or vaccine composition comprising eight isolated epitopes consisting of YLSGANLNV (SEQ. ID. NO: 1), IMIGVLVGV (SEQ. ID. NO: 2), KLBPVQLWV (SEQ. ID. NO: 3), SMPPPGTRV (SEQ. ID. NO: 4), KVAELVHFL (SEQ. ID. NO: 5), YLQLVFGIEV (SEQ. ID. NO: 6), RLLQETELV (SEQ. ID. NO: 7), and, VVLGVVFGI (SEQ. ID. NO: 8).Type: GrantFiled: April 5, 2000Date of Patent: August 5, 2003Assignee: Epimmune Inc.Inventors: John D. Fikes, Alessandro Sette, John Sidney, Scott Southwood, Esteban Celis, Elissa A. Keogh, Robert Chesnut
-
Publication number: 20030143672Abstract: Heteroclitic analogs of Class I epitopes are prepared by providing conservative or semi-conservative amino acid substitutions at positions 3 and/or 5 and/or 7 of these epitopes. The analogs are useful in eliciting immune responses with respect to the corresponding wildtype epitopes.Type: ApplicationFiled: April 5, 2002Publication date: July 31, 2003Applicant: Epimmune, Inc.Inventors: Shabnam Tangri, Alessandro Sette, Glenn Ishioka, John D. Fikes
-
Patent number: 6534482Abstract: The present invention relates to nucleic acid vaccines encoding multiple CTL and HTL epitopes and MHC targeting sequences.Type: GrantFiled: May 13, 1999Date of Patent: March 18, 2003Assignee: Epimmune, Inc.Inventors: John D. Fikes, Gary G. Hermanson, Alessandro Sette, Glenn Y. Ishioka, Brian Livingston, Robert W. Chesnut